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Background
Angiogenesis is an important pathway in tumour growth and
progression. Angiogenesis is regulated by several classical fac-
tors, Vascular Endothelial Growth Factor being the most
important. On the other hand tryptase, a serine protease
stored and released from mast cells (MCs) granules has been
identified as a new non-classical angiogenetic factor. Tryptase
is an agonist of the proteinase-activated receptor-2 (PAR-2) a
G protein involved in cellular proliferation and angiogenesis.
In this study, we have evaluated the correlations between the
number of MCs positive to tryptase (MCDPT), the number
of breast cancer cells positive to PAR-2 (BC-PAR-2) and
microvascular density (MVD) in a series of 97 primary T1-3,
N0-2 M0 female breast cancer by means of immuno-
histochemistry and image analysis methods.
Materials and methods
Six-micrometers thick serial sections of formalin-fixed and
paraffin-embedded bioptic tumor samples were obtained.
Then sections were microwaved at 500 W for 10 min. and
treated with a 3% hydrogen peroxide solution. Sections
were incubated with primary human-specific antibodies:
monoclonal anti-tryptase (clone AA1; Dako, Glostrup,
Denmark), goat polyclonal anti NH2 terminal of PAR-2
(clone N-19; sc-8206 Santa Cruz Biotecnology), and mono-
clonal anti-CD34 (QB-END 10; Bio-Optica Milan, Italy).
Biotinylated secondary antibody, avidin-biotin peroxidase
complex, and 3-amino-9-ethylcarbazole were in turn uti-
lised. In serial sections “hot spots” were selected at low
magnification and both individual vessels, single tryptase-
positive MCs and breast cancer cells positive to PAR-2
were counted at ×400.
Results
Data demonstrated a significant correlation between
MCDPT, BC-PAR-2 and MVD to each other (r = ranging
from 0.71 to 0.87; p: ranging from 0.001 to 0.003 by Pearson’s
analysis respectively). No correlation concerning MCDPT,
BC-PAR-2, MVD and the main clinical pathological features
was found.
Conclusions
Published in vitro data suggest that tryptase may increase
capillary growth and endothelial cell proliferation. On the
other hand tryptase induce angiogenesis by activation of
PAR-2 in vascular endothelial cells and breast cancer cells
lines. According to these experimental data our results sug-
gest that tryptase-positive MCs, PAR-2 and MVD paralleled
to each other thus underlying a role in in vivo breast cancer
angiogenesis. In this context several tryptase inhibitors such
as gabexate mesilate and nafamostat mesilate might be
evaluated in clinical trials as a new antiangiogenetic drugs.
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